Vanguard Group Inc. Sells 63,876 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Vanguard Group Inc. reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,282,666 shares of the specialty pharmaceutical company’s stock after selling 63,876 shares during the period. Vanguard Group Inc. owned 7.08% of Collegium Pharmaceutical worth $65,398,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of COLL. KLP Kapitalforvaltning AS bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $736,000. Hillsdale Investment Management Inc. grew its stake in Collegium Pharmaceutical by 1.0% in the fourth quarter. Hillsdale Investment Management Inc. now owns 116,200 shares of the specialty pharmaceutical company’s stock worth $3,329,000 after purchasing an additional 1,100 shares during the period. Summit Global Investments bought a new position in Collegium Pharmaceutical in the fourth quarter worth $232,000. Teacher Retirement System of Texas lifted its position in Collegium Pharmaceutical by 16.6% during the fourth quarter. Teacher Retirement System of Texas now owns 9,568 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 1,363 shares during the period. Finally, Intech Investment Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 593.7% during the 4th quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company’s stock valued at $1,923,000 after buying an additional 57,455 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently issued reports on COLL shares. Piper Sandler lowered their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Trading Down 6.4 %

NASDAQ:COLL opened at $24.67 on Friday. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29. The stock has a market cap of $792.70 million, a price-to-earnings ratio of 10.63 and a beta of 0.76. The company’s 50 day moving average price is $29.23 and its 200-day moving average price is $31.67. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 26,067 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the transaction, the executive vice president now directly owns 108,137 shares of the company’s stock, valued at $3,081,904.50. This represents a 19.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares in the company, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 in the last 90 days. 3.98% of the stock is currently owned by insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.